125 related articles for article (PubMed ID: 28608988)
1. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes: comment.
Gaikwad T; Ghosh K; Shetty S
J Thromb Haemost; 2017 Aug; 15(8):1708. PubMed ID: 28608988
[No Abstract] [Full Text] [Related]
2. Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes.
Baranova EV; Verhoef TI; Ragia G; le Cessie S; Asselbergs FW; de Boer A; Manolopoulos VG; Maitland-van der Zee AH;
J Thromb Haemost; 2017 Mar; 15(3):465-472. PubMed ID: 28063245
[TBL] [Abstract][Full Text] [Related]
3. A network meta-analysis of CYP2C9, CYP2C9 with VKORC1 and CYP2C9 with VKORC1 and CYP4F2 genotype-based warfarin dosing strategies compared to traditional.
Sridharan K; Sivaramakrishnan G
J Clin Pharm Ther; 2021 Jun; 46(3):640-648. PubMed ID: 33346393
[TBL] [Abstract][Full Text] [Related]
4. The effects of
Akdeniz CS; Cevik M; Canbolat IP; Yurdakul S; Cagatay P; Ciftci C; Karaalp A; Susleyici B
Future Cardiol; 2020 Nov; 16(6):645-654. PubMed ID: 32583677
[No Abstract] [Full Text] [Related]
5. Extremely low therapeutic doses of acenocoumarol in a patient with
Chaidaroglou A; Kanellopoulou T; Panopoulos G; Stavridis G; Degiannis D
Pharmacogenomics; 2019 Apr; 20(5):311-317. PubMed ID: 30983536
[TBL] [Abstract][Full Text] [Related]
6. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
[TBL] [Abstract][Full Text] [Related]
7. The VKORC1 and CYP2C9 genotypes significantly effect Vitamin K antagonist dosing only in patients over the age of 20years.
Nowak-Göttl U; Dietrich K; Kruempel A; Geisen C; Mitchell LG
Blood Cells Mol Dis; 2017 Sep; 67():54-58. PubMed ID: 28284562
[TBL] [Abstract][Full Text] [Related]
8. Warfarin pharmacogenetics.
Johnson JA; Cavallari LH
Trends Cardiovasc Med; 2015 Jan; 25(1):33-41. PubMed ID: 25282448
[TBL] [Abstract][Full Text] [Related]
9. VKORC1 and CYP2C9 genotype distribution in Asian countries.
Gaikwad T; Ghosh K; Shetty S
Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
Ghozlan MF; Foad DA; Darwish YW; Saad AA
Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.
Johnson JA; Caudle KE; Gong L; Whirl-Carrillo M; Stein CM; Scott SA; Lee MT; Gage BF; Kimmel SE; Perera MA; Anderson JL; Pirmohamed M; Klein TE; Limdi NA; Cavallari LH; Wadelius M
Clin Pharmacol Ther; 2017 Sep; 102(3):397-404. PubMed ID: 28198005
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Brandão LR; Ito S
Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a Novel Warfarin Dosing Algorithm for Korean Patients With
Cho EH; Lee K; Yang M; Choi R; Baek SY; Sohn I; Kim JS; On YK; Bang OY; Cho HJ; Lee SY
Ann Lab Med; 2020 May; 40(3):216-223. PubMed ID: 31858761
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetic variants influence vitamin K anticoagulant dosing in patients with mechanical prosthetic heart valves.
Koshy L; Vb R; M M; Ben MP; Kishor P; Sudhakaran PR; Abdullakutty J; Venugopal K; Zachariah G; Mohanan PP; Harikrishnan S; G S
Pharmacogenomics; 2022 Jun; 23(8):475-485. PubMed ID: 35608144
[No Abstract] [Full Text] [Related]
15. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China.
Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J
J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675
[TBL] [Abstract][Full Text] [Related]
16. Warfarin, genes, and the (health care) environment.
Kazi DS; Hlatky MA
JAMA Intern Med; 2014 Aug; 174(8):1338-9. PubMed ID: 24934523
[No Abstract] [Full Text] [Related]
17. The Influence of VKORC1 Polymorphisms on Warfarin Doses in Thai Patients with Deep Vein Thrombosis.
Sermsathanasawadi N; Sritongsathian C; Pongrattanaman N; Praditsuktavorn B; Hongku K; Wongwanit C; Ruangsetakit C; Chinsakchai K; Mutirangura P; Poungvarin N
J Med Assoc Thai; 2015 Jun; 98(6):549-54. PubMed ID: 26219158
[TBL] [Abstract][Full Text] [Related]
18. Validation of a proposed warfarin dosing algorithm based on the genetic make-up of Egyptian patients.
Ekladious SM; Issac MS; El-Atty Sharaf SA; Abou-Youssef HS
Mol Diagn Ther; 2013 Dec; 17(6):381-90. PubMed ID: 23839801
[TBL] [Abstract][Full Text] [Related]
19. Prediction of the impact of
Asari K; Takahashi H
Pharmacogenomics; 2020 Aug; 21(12):853-862. PubMed ID: 32700644
[No Abstract] [Full Text] [Related]
20. Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients.
Cho SM; Lee KY; Choi JR; Lee KA
Yonsei Med J; 2016 May; 57(3):635-40. PubMed ID: 26996562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
